PanCareSurPass Project HL7 FHIR Implementation Guide
1.0.0 - release 150

PanCareSurPass Project HL7 FHIR Implementation Guide, published by PanCareSurPass Project. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/pcsp/ and changes regularly. See the Directory of published versions

## ValueSet: Risk Factors

Official URL: http://hl7.eu/fhir/ig/pcsp/ValueSet/vs-riskfactor-eu-pcsp | Version: 1.0.0
Active as of 2025-10-16 | Computable Name: RiskFactor

Risk Factors used by the PCSP algorithm

References

- Observation: Risk Factor

### Logical Definition (CLD)

- Include all codes defined in `http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` version 📦1.0.0

### Expansion

Expansion performed internally based on codesystem Risk Factors v1.0.0 (CodeSystem)

This value set contains 112 concepts

System | Code | Display (en) | JSON | XML
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 1.1 | RT to a vol exposing the thyroid gland |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 1.2 | TBI |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 1.3 | MIBG therapy (I-131 MIBG therapy) |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 2.1 | RT >= 10 Gy to a vol exposing the breasts |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 2.2 | OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 3.1 | RT >= 35 Gy to a vol exposing the heart |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 3.2 | Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2 |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 3.3 | RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2 |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 4.1 | Alkylating agents |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 4.2 | RT to a vol exposing the testes |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 4.3 | Including TBI |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 5.1 | RT >=12 Gy to a vol exposing the testicles |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 6.3 | Surgery to the spinal cord, sympathetic nerves or pelvis |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 6.4 | Hypogonadal |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 7.2 | RT to a vol exposing the ovaries |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 8.1 | RT >= 30 Gy to a vol exposing the head or the brain |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 8.2 | Cisplatin (with or without carboplatin > 1500 mg/m2) |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 9.1 | RT to a vol exposing the pancreas |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 10.2 | HSCT |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 11.1 | RT to a volume exposing the hypothalamus or pituatary gland |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 11.3 | Hypothalamic or pituitary tumour |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 11.4 | Neurosurgery of the hypothalamus or pituitary gland |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 12.1 | RT to a vol exposing the kidneys, heart and associated large vessels |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 12.3 | Nephrectomy |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 12.4 | Ifosfamide |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 12.5 | Platinium based chemotherapy |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 12.6 | Nitrosureas |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 12.7 | Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously) |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 13.1 | Cranial and/or spinal RT |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 13.3 | Methotrexate |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 13.4 | Gonadal failure |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 13.5 | Growth hormone deficiency |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 13.6 | Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 13.7 | HSCT, especially with an history of GVHD |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 14.3 | High dose RT |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 15.1 | Radiotherapy to a vol exposing the HP region >= 30 Gy |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 15.2 | Surgery near or within the HP region |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 15.3 | CNS tumours near or within the HP region |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 16.1 | Radiotherapy to a vol exposing the HP region< 30 Gy |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 16.2 | Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD) |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 17.1 | Radiotherapy to a vol exposing the HP region |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 17.5 | hydrocephalus or cerebrospinal fluid shunt |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 19.3 | Radioiodine therapy (I-131 ablation therapy) |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 19.5 | Allogenic HSCT |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 19.6 | Total thyroidectomy |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 20.1 | RT to a vol exposing the head, brain or neck |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 21.1 | History of a central nervous system tumor |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 21.2 | RT to a vol exposing the brain ANY DOSE |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 21.4 | Brain surgery |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 21.5 | High dose cytarabine IV (intravenous) |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 21.6 | High dose MTX IV |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 21.7 | Any Chemotherapy IT (intrathecal) |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 22.1 | Vinca-Alkaloids |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 22.2 | Cisplatin or carboplatin |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 23.1 | RT to a vol exposing the lens |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 24.1 | RT to a vol exposing the eye and orbit |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 25.1 | RT to a vol exposing the craniofacial area, especially after high doses and at a young age |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 25.3 | Surgery to the face, especially at a young age |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 26.1 | Surgery of the spine |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 26.2 | Surgery of the chest (Does not include CVC pose) |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 26.3 | RT to a vol exposing the spine |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 26.4 | Spinal or paraspinal malignancies |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 27.1 | Cyclophosphamide |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 27.3 | RT to a vol exposing the bladder |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 27.5 | Cystectomy |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 27.6 | Hysterectomy |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 27.7 | Pelvic surgery |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 27.8 | Spinal cord surgery |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 28.1 | RT to a vol exposing the uterus only female |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 29.1 | RT to a vol exposing the oral cavity or salivary glands |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 29.4 | Chemotherapy |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 30.1 | RT to a vol exposing the gastro-intestinal tract |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 30.3 | Oesophageal surgery |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 30.4 | Abdominal surgery |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 30.5 | With a history of chronic GVHD |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 31.1 | Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2 |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 32.1 | RT to a vol exposing the lungs |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 32.3 | Bleomycin |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 32.4 | Busulfan |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 32.5 | BCNU Carmustine |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 32.6 | CCNU Lomustine |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 32.7 | Thoracic surgery |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 33.1 | Cisplatin Any dose |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 33.2 | Ifosfamide Any dose |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 33.3 | Carboplatin Any dose |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 34.1 | RT to a volume exposing the liver |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 34.10 | Chronic GVHD |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 34.11 | Liver surgery |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 34.3 | HSCT (irrespective of GVHD) |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 34.5 | Mercaptopurine Thioguanine |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 34.6 | Dactinomycin |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 34.8 | Chronic viral hepatitis |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 34.9 | Sinusoidal obstruction syndrome |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 35.1 | HSCT (irrespective of GVHD) |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 35.2 | Multiple red blood cell transfusions |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 36.1 | Splenectomy |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 36.2 | RT >= 10 Gy to a vol exposing the spleen |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 36.3 | Allogenic HSCT (with or without TBI) |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 36.4 | Autologus HSCT conditioned with TBI |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 37.1 | Hereditary cancer sd |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 38.1 | Any RT including TBI (predominantly in the RT field) |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 38.2 | HSCT Especially with a history of skin GvHD |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 39.1 | RT to a vol exposing the colon and rectum |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 40.1 | RT to a vol exposing the oral cavity |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 41.2 | Anthracyclines and/or Mitoxantrone |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 41.3 | Epipodophyllotoxins or autologous |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 41.4 | Autologous haematopoietic stem cell transplant |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 42.1 | Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis) |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 45.1 | RT to a vol exposing the head or brain |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 46.1 | RT between 15 and 35 Gy to a vol exposing the heart |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 46.2 | Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2 |  |
`http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp` | 47.1 | RT to a vol exposing the kidney or urinary tract |  |

Explanation of the columns that may appear on this page:

Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System | The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code | The code (used as the code in the resource instance)
Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition | An explanation of the meaning of the concept
Comments | Additional notes about how to use the code